Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q1 2018 · 10-Q
Revenue$4.11M$4.11M+91.1% vs Q1 2017 Net Income-$189.18K-$189.18KN/M vs Q1 2017 EPS Diluted-$0.02-$0.02N/M vs Q1 2017 Gross Profit$2,104,145+173.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Operating Cash Flow-$787,388N/M Free Cash Flowderived-$791,191N/M Margins · derivedGross margin51.2%+15.4 pt vs Q1 2017
Operating margin-4.6%+36.7 pt vs Q1 2017
Net margin-4.6%+36.4 pt vs Q1 2017
ended Mar 31, 2018 · filed May 2, 2018 · 32 d after period end